Analyst Price Targets — AMRN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 6, 2023 5:23 am | — | Jefferies | $3.00 | $1.26 | Benzinga | Jefferies Upgrades Amarin Corp to Buy, Raises Price Target to $3 |
| May 24, 2022 7:21 am | — | Goldman Sachs | $1.50 | $1.41 | Benzinga | Goldman Sachs Maintains Sell on Amarin Corp, Lowers Price Target to $1.5 |
| May 5, 2022 12:00 am | Carl Byrnes | Northland Securities | $2.00 | $1.56 | TipRanks Contributor | Amarin Nosedives on Disappointing Quarterly Results |
Latest News for AMRN
Amarin (NASDAQ: AMRN) executives told investors that 2025 marked a "substantial achievement" year as the company advanced a strategic pivot toward a more partnered international commercial model and executed a global restructuring aimed at lowering its operating expense base. On the company's fourth-quarter and full-year 2025 earnings call, management highlighted a new long-term agreement with Recordati
AMRN swings to Q4 profit and beats estimates, but revenues decline 21% as Vascepa sales slide and shares fall 9% on the mixed results.
Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript
DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month emphasizing a message that cannot wait: the United States has an opportunity to significantly reduce heart attacks, strokes, and cardiovascular deaths by prioritizing the…
AMRN, AMTB and AAWH have been added to the Zacks Rank #5 (Strong Sell) List on January 28th, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMRN.
U.S. House Trading
No House trades found for AMRN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.